NYSE: CAHCardinal Health

    Cardinal Health Q1 FY2027 Results: Net Income $554 Million on Revenue of $67.51 Billion

    • US stocks
    • Earnings
    • Health Care

    Cardinal Health (NYSE: CAH) said on 5 Nov 2026 that revenue for the first quarter of fiscal 2027, the three months to 30 Sep 2026, was $67.5 billion and GAAP net earnings attributable to Cardinal Health were $554.0 million. GAAP diluted EPS was $2.38, and non-GAAP diluted EPS, a company-defined measure, was $3.26.

    Key highlights

    • Revenue (GAAP): $67.5 billion, up 5.5% YoY
    • Operating income (GAAP): $753.0 million, up 12.7% YoY
    • Net income attributable to the company (GAAP): $554.0 million, up 23.1% YoY
    • Diluted EPS (GAAP): $2.38, up 26.6% YoY
    • Non-GAAP diluted EPS (company-defined): $3.26

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ1 FY2027Q1 FY2026YoY
    Revenue67,513.064,009.0+5.5%
    753.0668.0+12.7%
    554.0450.0+23.1%
    Diluted EPS ($)2.381.88+26.6%

    Figures are in $ million except EPS; YoY compares with Q1 FY2026. Q1 FY2027 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    Revenue rose 5.5% from a year earlier, to $67.5 billion from $64.0 billion. Operating income was 1.1% of revenue this quarter, against 1.0% a year earlier, and net income was 0.8% of revenue, against 0.7%, which is 0.1 percentage points higher on each measure.

    Non-GAAP figures exclude items the company names

    The company's non-GAAP measures exclude restructuring and employee severance, amortization and other acquisition-related costs, acquisition-related cash and share-based compensation costs, impairments and gains or losses on disposal of assets, litigation recoveries or charges, and the impairment of its equity interest in Outcomes. On that basis non-GAAP operating earnings were $1,001 million, up 17%, and non-GAAP diluted EPS was $3.26, up 28%.

    The company credits higher non-GAAP operating earnings, a smaller share count and a lower effective tax rate for the faster growth in non-GAAP diluted EPS.

    Pharmaceutical and Specialty Solutions profit rose

    Pharmaceutical and Specialty Solutions revenue was $62.6 billion, up 6%, and segment profit was $783.0 million, up 17%. The company attributes the profit increase to contributions from brand and specialty products and positive generics program performance.

    Global Medical Products and Distribution revenue was $3.19 billion, approximately flat, and segment profit was $33.0 million, down from $46 million a year earlier. The company attributes the decline to unfavorable distribution and foreign exchange impacts, partly offset by growth in Cardinal Health Brand.

    Fiscal 2027 non-GAAP EPS outlook was raised

    The company now expects fiscal 2027 non-GAAP diluted EPS of $12.80 to $13.00, up from $12.40 to $12.60. It also expects a non-GAAP effective tax rate of 18.5% to 19.5%, down from 19.0% to 20.0%, and diluted weighted average shares of 231 million to 232 million, from about 233 million. The company says the EPS range is 17% to 19% growth from its FY26 ex-tariff refund baseline of $10.95.

    The company does not give a GAAP outlook, saying certain items cannot be reasonably estimated. It raised its Pharmaceutical and Specialty Solutions profit growth expectation to 10% to 12% and its Other profit growth expectation to 17% to 20%.

    Inference

    Diluted weighted average shares were 233 million, against 239 million a year earlier, and the company completed its $500.0 million share repurchase program in the quarter. The company ties the lower share count guidance to the timing of a $500 million accelerated share repurchase in the first quarter.

    The release does not give the price of the AdaptHealth Diabetes Health acquisition or the financial terms of the CVS Health agreement. The company expects to complete the AdaptHealth acquisition in the third quarter of fiscal 2027.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts